62
Participants
Start Date
February 21, 2018
Primary Completion Date
January 25, 2023
Study Completion Date
January 25, 2024
nivolumab-daratumumab
nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
nivolumab-daratumumab with low-dose cyclophosphamide
nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
Rijnstate ziekenhuis, Arnhem
Radboud MC, Nijmegen
MUMC, Maastricht
UMC Groningen, Groningen
Albert Schweitzer Ziekenhuis, Dordrecht
Meander MC, Amersfoort
St. Antonius Ziekenhuis, Nieuwegein
UMC Utrecht, Utrecht
VU University Medical Center, Amsterdam
Collaborators (2)
Erasmus Medical Center
OTHER
UMC Utrecht
OTHER
Maastricht University Medical Center
OTHER
Meander Medical Center
OTHER
St. Antonius Hospital
OTHER
Isala
OTHER
Albert Schweitzer Hospital
OTHER
Radboud University Medical Center
OTHER
University Medical Center Groningen
OTHER
Rijnstate Hospital
OTHER
Amsterdam UMC, location VUmc
OTHER